Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSBUET)

Drug Name

SB220025 Drug Info

Synonyms

SB220025; 3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole

Indication

Disease Entry	ICD 11	Status	REF
Arthritis	FA20	Terminated	[1]

Cross-matching ID

PubChem CID: 5164
ChEBI ID: CHEBI:82713
CAS Number: CAS 165806-53-1
TTD Drug ID: DMSBUET

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Preclinical Drug(s)

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Extracellular signal-regulated kinase 2 (ERK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[3]
HH2710	DM0C5MV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
ASTX029	DMVZXIA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
VAN-10-4-eluting stent	DM3ZW6A	Artery stenosis	BD52	Phase 1	[6]
GDC-0994	DMFC2OY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
JSI-1187	DMVJWBS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
LY3214996	DMFDAY7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[10]
COR-D	DMLXMCB	T-cell leukaemia	2A90	Preclinical	[11]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[13]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[13]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[14]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[15]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[13]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[16]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[16]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[16]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[16]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Extracellular signal-regulated kinase 2 (ERK2)	TT4TQBX	MK01_HUMAN	Inhibitor	[2]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6038).
2	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3	DOI: 10.1158/1538-7445.AM2015-4693
4	Clinical pipeline report, company report or official report of HaiHe Biopharma.
5	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
6	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
7	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
8	National Cancer Institute Drug Dictionary (drug name JSI1187).
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
11	Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
12	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
13	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
14	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
15	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
16	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.